Among GLP1-RAs, liraglutide has obtained the most compelling evidence so far about the potential impact of GLP1-RAs in NASH treatment due to the phase II LEAN clinical trial (NCT01237119). This evidence concerns the gene GCG and metabolic dysfunction-associated steatohepatitis.